Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2009-04-09
2011-11-15
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C544S337000
Reexamination Certificate
active
08058263
ABSTRACT:
The present invention relates to compounds of formula Iwherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
REFERENCES:
patent: 6855715 (2005-02-01), Liebeschuetz et al.
patent: 2003/0060474 (2003-03-01), Bryant et al.
patent: 2005/0038037 (2005-02-01), Bryant et al.
patent: 2005/0065163 (2005-03-01), Bryant et al.
patent: 2008/0194576 (2008-08-01), Caroff et al.
patent: 2008/0234272 (2008-09-01), Binkert et al.
patent: 2010/0261678 (2010-10-01), Caroff et al.
patent: 0 407 200 (1991-01-01), None
patent: 53-073586 (1978-06-01), None
patent: WO 02/098856 (2002-12-01), None
patent: WO 2004/052366 (2004-06-01), None
patent: WO 2004052366 (2004-06-01), None
patent: WO 2004/092189 (2004-10-01), None
patent: WO 2006/114774 (2006-11-01), None
patent: WO 2008/044217 (2008-04-01), None
patent: WO 2008/050301 (2008-05-01), None
patent: WO 2009/069100 (2009-06-01), None
patent: WO 2009/080226 (2009-07-01), None
patent: WO 2009/080227 (2009-07-01), None
patent: WO 2009/125365 (2009-10-01), None
patent: WO 2009/125366 (2009-10-01), None
patent: WO 2010/116328 (2010-10-01), None
patent: WO 2010/122504 (2010-10-01), None
Norgard, Expert Opin. Invest.Drugs vol. 18(8), pp. 1219-1230 (2009).
Bartoli, G., et al., “Reaction of Dianions of Acyclic β-Enamino Ketones with Electrophiles. 3. Nitriles: Synthesis of Pyridine and Pyrimidine Derivatives”, J. Org. Chem., vol. 57, pp. 6020-6025, (1992).
Furstner, A., et al., “Iron-Catalyzed Cross-Coupling Reactions”, J. Am. Chem. Soc., vol. 124, pp. 13856-13863, (2002).
Gould, P.L., “Salt Selection for Basic Drugs”, International Journal of Pharmaceutics, vol. 33, pp. 201-217, (1986).
Parlow, J.J., et al., “Piperazinyl-glutamate-pyridines as Potent Orally Bioavailble P2Y12 Antagonists for Inhibition of Platelet Aggregation”, Bioorganic & Medicinal Chemistry Letters, vol. 19, pp. 4657-4663, (2009).
Parlow, J.J., et al., “Piperazinyl-glutamate-pyrimidines as Potent P2Y12 Antagonists for Inhibition of Platelet Aggregation”, Bioorganic & Medicinal Chemistry Letters, vol. 19, pp. 6148-6156, (2009).
Remington, The Science and Practice of Pharmacy, 21stEdition (2005), Part 5, “Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins].
Shao, B., et al., “Phenoxyphenyl Pyridines as Novel State-Dependent, High-Potency Sodium Channel Inhibitors”, J. Med. Chem., vol. 47, pp. 4277-4285, (2004).
Amir, J., et al., “Treatment of Thrombotic Thrombocytopenic Pupura with Antiplatelet Drugs”, Blood, vol. 42, No. 1, pp. 27-33 Jul. 1973.
Antithrombotic Trialists' Collaboration, “Collaborative Meta-Analysis of Randomised Trials of Antiplatelet Therapy for Prevention of Death, Myocardial Infarction, and Stroke in High Risk Patients”, British Medical Journal, vol. 324, pp. 71-86, 2002.
Balduini, C.L., et al., “Platelet Aggregation in Platelet-Rich Plasma and Whole Blood in 120 Patients with Myeloproliferative Disorders”, Coagulation and Transfusion Medicine, vol. 95, No. 1, pp. 82-86, Jan. 1991.
Bertrand, Michel. E., “Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary Stenting: . . . ” Circulation, vol. 98, pp. 1597-1603, 1998.
Born G.V.R., et al., “The Aggregation of Blood Platelets”, J. Physiol., vol. 168, pp. 178-195, (1963).
Brighton, T.A., et al., “Antiphospholipid Antibodies and Thrombosis”, Bailliere's Clinical Haematology, vol. 7, No. 3, pp. 541-557, Sep. 1994.
Caprie Steering Committee, “A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)”, The Lancet, vol. 348, pp. 1329-1339, Nov. 16, 1996.
Collins, C.E. et al., “Review Article:Platelets in Inflammatory Bowel Diease-Pathogenic Role and Therapeutic Implications”, Aliment Pharmacol. Ther., vol. 11, pp. 237-247, 1997.
Database Chemcats, Chemical Abstracts Service, Columbus, OH, USA; XP002420714; Order No. (ON) CGX-3221820.
Database Chemcats, Chemical Abstracts Service, Columbus, OH, USA; XP002420715; Order No. (ON): 15569369, 15467386.
Davies, M.J., et al., “Intramyocardial Platelet Aggregation in Patients with Unstable Angina Suffering Sudden Ischemic Cardiac Death”, Pathophysiology and Natural History—Platelets, Circulation, vol. 73, No. 3, pp. 418-427, 1986.
Felfernig-Boehm, D., et al., “Early Detection of Preeclampsia by Determination of Platelet Aggregability”, Thrombosis Research, vol. 98, pp. 139-146, 2000.
Feokistov et al., “Adenosine A2B receptors, Pharmacological Reviews”, vol. 49, No. 4, pp. 381-402, 1997.
Fox, K.A.A., et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome: The Clidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial, Circulation, vol. 110, pp. 1202-1208, 2004.
Halushka, P.V., et al., “Protective Effects of Aspirin in Endotoxic Shock”, The Journal of Pharmacology and Experimental Therapeutics, vol. 218, No. 2, pp. 464-469, 1981.
Hovens, M.M.C., et al., “Aspirin in the Prevention and Treatment of Venous Thromboembolism”, Journal of Thrombosis and Haemostasis, vol. 4, pp. 1470-1475, 2006.
Iyer, R.P., et al., “Synthesis of lodoalkylacylates and their Use in the Preparation of S-Alkyl Phosphorothiolates”, Synthetic Communications, vol. 25(18), pp. 2739-2749, (1995).
Kharbanda, R.K., et al., “Prevention of Inflammation-Induced Endothelial Dysfunction: A Novel Vascula-Protective Action of Aspirin”, Circulation, vol. 105, pp. 2600-2604, 2002.
Megalopoulos, a., et al., “Recurrent Arterial Thromboses in a Woman with Heparin Induced Thrombocytopenia, Successfully Managed with Iloprost Followed by Clopidogrel. An Alternative Therapeutic Option for Heparin Induced Thrombocytopenia Type II Syndrome”, International Angiology, vol. 25, No. 1, pp. 84-89, Mar. 2006.
Mehta, S.R., et al., “Effects of Pretreatment with Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention: The PCI-CURE Study”, The Lancet, vol. 358, pp. 527-533, Aug. 18, 2001.
Office Action dated Oct. 28, 2010, U.S. Appl. No. 11/912,545.
Office Action dated Jan. 29, 2011, U.S. Appl. No. 12/445,352.
Parlow, John J. et al., “Piperazinyl-glutamate-pyrimidines as potent P2Y12antagonists for inhibition of platelet aggregation”, 2009, Bioorganic & Medicinal Chemistry Letters, pp. 6148-6156.
Payne, D.A., et al., “Beneficial Effects of Clopidogrel Combined with Aspirin in Reducing Cerebral Emboli in Patients Undergoing Carotid Endarterectomy”, Circulation, vol. 109, pp. 1476-1481, 2004.
Stathakis, N.E., et al., Platelet Dysfunction in Essential Thrombocythaemia, Annals of Clinical Research, vol. 6, pp. 198-202, 1974.
Thorsen, C. A., et al., “The Treatment of the Hemolytic-Uremic Syndrome with Inhibitors, of Platelet Function”, The American Journal of Medicine, vol. 66, pp. 711-716, Apr. 1979.
Triadou, P., et al., “Platelet Function in Sickle Cell Disease During Steady State”, Nouvelle Revue Francaise Hematologie, vol. 32, pp. 137-142, 1990.
University of Perugia, “Aspirin for the Prevention of Recurrent Venous Thromboembolism and Cardiovascular Events”, pp. 1-3, ClinicalTrials.gov/ct/show/NCT00222677, Sep. 13, 2005.
Yao, S., et al., “Clopidogrel is More Effective Than Aspirin as Adjuvant Treatment to Prevent Reocclusion After Thrombolysis”, Am.
Caroff Eva
Hilpert Kurt
Hubler Francis
Meyer Emmanuel
Renneberg Dorte
Actelion Pharmaceuticals Ltd
Bernhardt Emily
Hoxie & Associates LLC
LandOfFree
Substituted 2-phenyl-pyridine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 2-phenyl-pyridine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2-phenyl-pyridine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4277710